Sleep Apnea - Pipeline Review, H2 2016

Date: August 17, 2016
Pages: 60
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S547F9C6CA9EN
Leaflet:

Download PDF Leaflet

Sleep Apnea - Pipeline Review, H2 2016
Sleep Apnea - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Sleep Apnea - Pipeline Review, H2 2016’, provides an overview of the Sleep Apnea pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sleep Apnea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sleep Apnea and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Sleep Apnea
  • The report reviews pipeline therapeutics for Sleep Apnea by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Sleep Apnea therapeutics and enlists all their major and minor projects
  • The report assesses Sleep Apnea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Sleep Apnea
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Sleep Apnea
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Sleep Apnea pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Sleep Apnea Overview
Therapeutics Development
Pipeline Products for Sleep Apnea - Overview
Pipeline Products for Sleep Apnea - Comparative Analysis
Sleep Apnea - Therapeutics under Development by Companies
Sleep Apnea - Therapeutics under Investigation by Universities/Institutes
Sleep Apnea - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Sleep Apnea - Products under Development by Companies
Sleep Apnea - Products under Investigation by Universities/Institutes
Sleep Apnea - Companies Involved in Therapeutics Development
Galleon Pharmaceuticals
RespireRx Pharmaceuticals Inc.
SK Biopharmaceuticals Co., Ltd.
Vivus, Inc.
Sleep Apnea - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(phentermine + topiramate) ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CX-1739 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dronabinol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GAL-475 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GAL-475 Backups - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SKL-N05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Sleep Apnea - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sleep Apnea - Dormant Projects
Sleep Apnea - Discontinued Products
Sleep Apnea - Product Development Milestones
Featured News & Press Releases
Jun 14, 2016: Jazz Pharmaceuticals Presents New Data from a Human Abuse Liability Study for JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy or with Obstructive Sleep Apnea, at 30th Annual SLEEP Meeting
Feb 29, 2016: RespireRx Pharmaceuticals Announces Removal of FDA Clinical Hold on CX1739 and Initiation of Phase IIA Clinical Trial by March 31, 2016
Jun 08, 2015: Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Clinical Development Program Evaluating JZP-110 as a Potential Treatment of EDS Associated with Narcolepsy or with OSA
May 14, 2015: VIVUS Announces Scientific Presentations
May 04, 2015: Cortex Pharmaceuticals Announces Publication of Research Results on the Use of Ampakines CX1739 in the Treatment of Respiratory Disorders
May 04, 2015: Cortex Pharmaceuticals Announces Publication of Research Results on the Use of Ampakines CX1739 in the Treatment of Respiratory Disorders
May 15, 2014: VIVUS Announces Qsymia Presentation at the American Association of Clinical Endocrinologists
Jul 01, 2013: VIVUS Announces Initial Availability of Qsymia Through Certified Retail Pharmacies
Nov 12, 2012: Study Finds Significant Improvements In Patients With Obstructive Sleep Apnea Treated With Phentermine And Topiramate Extended-Release Capsules
Jan 09, 2012: VIVUS Provides Update On Regulatory Status Of Qnexa
Nov 03, 2011: FDA Accepts New Drug Application Filing For Qnexa
Apr 26, 2011: Cortex Receives US Patent For Lead AMPAKINE Molecule CX1739
Feb 02, 2011: Cortex’s Ampakine CX1739 Improves Respiratory Parameters In Obstructive Sleep Apnea Patients
Jan 07, 2010: VIVUS Announces Positive Results From Phase II Study Of Qnexa In Obstructive Sleep Apnea
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Sleep Apnea, H2 2016
Number of Products under Development for Sleep Apnea - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Sleep Apnea - Pipeline by Galleon Pharmaceuticals, H2 2016
Sleep Apnea - Pipeline by RespireRx Pharmaceuticals Inc., H2 2016
Sleep Apnea - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016
Sleep Apnea - Pipeline by Vivus, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Sleep Apnea - Dormant Projects, H2 2016
Sleep Apnea - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Sleep Apnea, H2 2016
Number of Products under Development for Sleep Apnea - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Sleep Apnea - Pipeline Review, Q4 2010 US$ 500.00 Nov, 2010 · 50 pages
Sleep Apnea - Pipeline Review, Q1 2011 US$ 500.00 Jan, 2011 · 32 pages
Sleep Apnea - Pipeline Review, Q3 2011 US$ 500.00 Jul, 2011 · 65 pages
Sleep Disorders - Pipeline Review, Q3 2011 US$ 500.00 Jul, 2011 · 136 pages

Ask Your Question

Sleep Apnea - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: